|本期目录/Table of Contents|

[1]张常喜,杨爱萍,冯丽丽.脉管通胶囊治疗动脉粥样硬化的临床疗效及安全性评价[J].宁夏医科大学学报,2018,(04):403-407.[doi:10.16050/j.cnki.issn1674-6309.2018.04.007]
 ZHANG Changxi,YANG Aiping,FENG Lili.Evaluation on the Clinical Effacy and Safety of Maiguantong Capsules in Treatment of Atherosclerosis[J].Ningxia Medical University,2018,(04):403-407.[doi:10.16050/j.cnki.issn1674-6309.2018.04.007]
点击复制

脉管通胶囊治疗动脉粥样硬化的临床疗效及安全性评价(PDF)
分享到:

《宁夏医科大学学报》[ISSN:1005-8486/CN:64-1029/R]

卷:
期数:
2018年04期
页码:
403-407
栏目:
论 著
出版日期:
2019-09-30

文章信息/Info

Title:
Evaluation on the Clinical Effacy and Safety of Maiguantong Capsules in Treatment of Atherosclerosis
作者:
张常喜1 杨爱萍2 冯丽丽1
(1. 宁夏回族自治区中医医院,银川 750021; 2. 宁夏保安康生物科技有限公司,银川 750021)
Author(s):
ZHANG Changxi1 YANG Aiping2 FENG Lili1
(1. Ningxia Traditional Chinese Medicine Hospital,Yinchuan 750021; 2. Ningxia Bao An Kang Biotechnology Co. ,Ltd,Yinchuan 750021)
关键词:
脉管通胶囊辛伐他汀动脉粥样硬化临床疗效安全性
Keywords:
Maiguantong capsulesimvastatinatherosclerosisclinical efficacysafety
分类号:
R543.5
DOI:
10.16050/j.cnki.issn1674-6309.2018.04.007
文献标志码:
A
摘要:
目的 探讨脉管通胶囊治疗动脉粥样硬化(atherosclerosis,AS)的临床疗效及安全性。方法 2015年4月-2017年11月在我院门诊及住院的AS斑块患者120例,按随机数字表法分为脉管通组和辛伐他汀组(n=60),两组患者均接受基础治疗,辛伐他汀组患者在基础治疗的同时给予口服辛伐他汀片10mg/次,1次/日;脉管通胶囊组在基础治疗的同时给予口服脉管通胶囊0.5g(5粒/次),3次/d;疗程均为12周。治疗前及治疗后12周测定两组患者血脂指标、颈总动脉中-内膜厚度、斑块积分和斑块面积,治疗12周时进行中医症候疗效判定。治疗前后检测两组患者的血糖、肝功能和肾功能指标,测12导联心电图,记录两组患者治疗期间的不良事件发生情况,以评价该药物的安全性。结果 治疗12周时两组患者甘油三酯(TG)、总胆固醇(TC)和低密度脂蛋白-胆固醇(LDL-C)水平、颈总动脉中-内膜厚度、斑块积分和面积均较治疗前降低(P均<0.05),高密度脂蛋白-胆固醇(HDL-C)水平较治疗前升高(P<0.05);治疗后两组患者TG、TC、LDL-C和HDL-C水平差异均无统计学意义(P均>0.05),脉管通胶囊组患者颈总动脉中-内膜厚度、斑块积分和面积均较辛伐他汀片组降低(P<0.05);治疗12周脉管通胶囊组患者中医症候临床疗效优于辛伐他汀片组(P<0.05)。治疗期间两组患者血糖水平、肝脏和肾脏功能指标差异均无统计学意义(P均>0.05);心电图检查未见明显改变,未收到患者报告的不良反应。结论 脉管通胶囊治疗动脉粥样硬化具有较好的临床效果和安全性。
Abstract:
Objective To investigate the clinical efficacy and safety of Maiguantong capsules in the treatment of atherosclerosis. Methods A total of 120 cases with carotid atherosclerotic plaque at outpatient or hospitalized from April 2015 to November 2017 were divided into Maiguantong capsules group and Simvastatin Group(n=60) according to the random number table. All patients in two groups received basic treatment. Patients in Simvastatin group were given oral simvastatin tablets,10mg/times,once a day beside the basic treatment. Patients in Maiguantong capsules group were given oral Maiguantong capsules 5 capsules/ times, 3 times a day for 12 weeks. Before and after treatment for 12 weeks,the blood lipid index,intima media thickness,plaque score and plaque area were measured. The curative effect of TCM syndrome was determined at 12 weeks. The blood glucose,liver function and renal function in two groups were determined before and after treatment. The 12 electrocardiogram was measured and the adverse reactions were recorded during the treatment period to evaluate the safety. Results At the 12 week of treatment,the levels of TG,TC and LDL-C in two groups were significantly decreased compared with those before treatment(P<0.05),and the level of HDL-C after treatment for 12 weeks was significantly increased compared with that before treatment(P<0.05),but there was no significant difference for TG,TC,LDL-C and HDL-C in two groups after treatment for 12 weeks (P<0.05). Intima media thickness,plaque score and plaque area in both groups after treatment for 12 week were significantly decreased in the two groups(P<0.05),but intima media thickness, plaque score and plaque area in Maiguantong capsules group were significantly decreased compared with those in Simvastatin group (P<0.05). Improvement on TCM syndrome in Maiguantong capsules group were significantly better than that in Simvastatin group(P<0.05). There were no significant changes for blood glucose,liver function and electrocardiogram in two groups during treatment(P>0.05),and no adverse reactions were reported. Conclusion Maiguantong capsule has a good clinical therapeutic effect and safety in the treatment of atherosclerosis.

参考文献/References:


[1] Wilson HM. Macrophages heterogeneity in atherosclerosis-implications for therapy[J]. J Cell Mol Med,2010, 14(8):2055-2065.
[2] 粱芳, 马玉梅, 魏德芝,等. 稳消方对颈动脉粥样硬化不稳定斑块影响的临床研究[J]. 中国医药导报,2016,13(1):121-125.
[3] 陈朝俊,李玥珺,胡建芳,等. 参七脉心通胶囊对颈动脉硬化患者动脉粥样硬化的影响[J]. 广东医学,2016,36(8):1228-1230.
[4] 华扬. 实用颈动脉与颅脑超声诊断学[M]. 2版. 北京:科学出版社,2004:185-187.
[5] Naghavi M,Libby P,Falk E,et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessmentstrategies:PartⅡ[J]. Circulation, 2003,108(15):1772-1778.
[6] 程康林,覃勇,陈仁山,等. 痰浊型冠心病患者痰浊证与颈动脉斑块的相关性分析[J]. 新中医,2006,38(8):0256-7415.
[7] 杜文婷,王臻楠,顾耘. 动脉粥样硬化的中西医认识概况[J]. 中西医结合心脑血管病杂志,2016,14 (22):2634-2637.
[8] 粱芳,马玉梅,魏德芝,等. 稳消方对颈动脉粥样硬化不稳定斑块影响的临床研究[J]. 中国医药导报,2016,13(1):121-125.
[9] 蓝丽康,吕锦,李洁,等. 阿托伐他汀钙稳定颈动脉粥样硬化斑块的远期效果评价[J]. 中西医结合心脑血管病杂志,2015,13(8):1035-1037.
[10] 莫祝宁,孔晓玲,韦兴来,等. 阿托伐他疗终末期肾脏病患者颈动脉粥样硬化前后的超声表现差异性研究[J]. 医学研究杂志,2016,45(10):124-127.
[11] Prati P,Tosetto A,Vanuzzo D,et al. Carotid intima media thickness and plaques can predict the occurrence of ischemic cerebrovascular events[J].Stroke,2008,39(9):2470-2476.
[12] Xu P,Lv L,Li S,et al. Use of high-resolution 3.0-T magnetic resonance imaging to characterize atherosclerotie plaques in patients with cerebral infarction[J]. Exp Ther Med,2015,10(6):2424-2428.
[13] Matsumoto N,Kimura K,Yokota C,et al. Early neurolog-ical deterioration represents recurrent attack in acute small non-lacunar stroke[J]. J Neurol Sci,2004,217(2):151-155.
[14] Vlachopoulos C,Aznaouridis K,Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness:a systematic review and meta-analysis E[J]. J Am Coll Cardiol,2010,55(13):1318-1327.
[15] 张纳,杨智航,项明慧,等. 超声评价2型糖尿病患者颈动脉病变与视网膜微血管病变相关性研究[J]. 中国医科大学学报,2014,43(8):728-732.
[16] Huang XZ,Wang ZY,Dai XH,et al. Velocity vector imaging of longitudinal mechanical properties of upstream and downstream shoulders and fibrous cap tops of human carotid atherosclerotic plaque[J]. Echocardiography,2013,30(2):211-218.
[17] 谢君,张慷. 速度向量成像技术对冠心病患者颈总动脉弹性的研究[J]. 重庆医学,2016,45(32):4499-4502.

相似文献/References:

[1]高红华,王雪莲.二次剖宫产136例临床分析[J].宁夏医科大学学报,2010,(02):286.
[2]王华,彭燕.血必净注射液治疗脓毒症的临床观察[J].宁夏医科大学学报,2010,(02):274.
[3]姜清茹,马玉芳,宋 梅,等.辛伐他汀对高脂血症大鼠主动脉平滑肌细胞凋亡的影响[J].宁夏医科大学学报,2012,(10):993.
 JIANG Qing-ru,MA Yu-fang,SONG Mei,et al.Effect of Simvastatin on Smooth Muscle Cells Apoptosis of Aorta in Hyperlipidemic Rats[J].Ningxia Medical University,2012,(04):993.
[4]纳 莉,徐支芳,巩慧慧,等.同型半胱氨酸致动脉粥样硬化的机制研究[J].宁夏医科大学学报,2012,(09):887.
 NA Li,XU Zhi-fang,GONG Hui-hui,et al.Induced Hyperhommocysteinemia in the Study of the Mechanisms of Otherosclerosis[J].Ningxia Medical University,2012,(04):887.
[5]欧向阳.纳洛酮在煤工尘肺合并肺性脑病中的应用[J].宁夏医科大学学报,2012,(08):851.
[6]单晓宇,刘敬霞,楚国庆,等.回药扎里奴思方对脑梗死患者颈动脉硬化的影响[J].宁夏医科大学学报,2012,(08):753.
 SHAN Xiao-yu,LIU Jing-xia,CHU Guo-qing,et al.Effect of Hui Medicine Zhalinusi Recipe on Carotid Atherosclerosis Changes in Patients with Cerebral Infarction in Patients[J].Ningxia Medical University,2012,(04):753.
[7]郭 静,张 伟,丁 黎,等.熊果苷制剂对豚鼠皮肤安全性及脱色作用的研究[J].宁夏医科大学学报,2012,(06):592.
 GUO Jing,ZHANG Wei,DING Li,et al.Safety and Decoloration of the Arbutin Preparations on the Skin of Guinea Pigs[J].Ningxia Medical University,2012,(04):592.
[8]赵 凯,钱月慧,程晓东.TNF-α、NF-κB在动脉粥样硬化闭塞症兔动脉中的表达变化[J].宁夏医科大学学报,2012,(01):14.
 ZHAO Kai,QIAN Yue-hui,CHENG Xiao-dong.The Level Changes of TNF-α 、NF-κB on Rabbit Artery with Atherosclerotic Occlusive Disease[J].Ningxia Medical University,2012,(04):14.
[9]李 录,贾绍斌.DNA甲基化与动脉粥样硬化的研究进展[J].宁夏医科大学学报,2013,(05):598.
[10]赵兴,郭健伟,刘欢,等.原发性高血压患者红细胞和血小板参数的变化与颈动脉粥样硬化的关系[J].宁夏医科大学学报,2013,(02):206.

备注/Memo

备注/Memo:
收稿日期:2017-07-06
基金项目:宁夏回族自治区重点研发计划项目(2015BY088);宁夏卫生计生委卫生系统科研项目(2016-NW-052)
作者简介:张常喜,主任医师,硕士研究生导师,研究方向:中西医结合心血管方向。
更新日期/Last Update: 2018-04-30